Wedbush Starts Harley-Davidson (HOG) at Outperform; Gradual Improvement in Retail Motorcycle Sales Trends
Tweet
Share
E-mailGet Alerts HOG Hot Sheet
Price: $27.03 -2.7%
Rating Summary:
8 Buy, 15 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
8 Buy, 15 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Wedbush initiates coverage on Harley-Davidson (NYSE: HOG) with a Outperform. PT $48.
Wedbush analyst says, "Given Harley-Davidson’s continued market share gains, a recovering retail environment for premium motorcycles, current dealer inventory restocking in the face of rising demand, and increased profitability and lower credit risk in the financing arm, we believe shares of HOG should trade at relatively in line to the peer group average 2012E P/E ratio of 16.5x."
For more ratings news on Harley-Davidson click here and for the rating history of Harley-Davidson click here.
Shares of Harley-Davidson closed at $40.14 yesterday.
Wedbush analyst says, "Given Harley-Davidson’s continued market share gains, a recovering retail environment for premium motorcycles, current dealer inventory restocking in the face of rising demand, and increased profitability and lower credit risk in the financing arm, we believe shares of HOG should trade at relatively in line to the peer group average 2012E P/E ratio of 16.5x."
For more ratings news on Harley-Davidson click here and for the rating history of Harley-Davidson click here.
Shares of Harley-Davidson closed at $40.14 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Harley-Davidson (HOG) PT Raised to $33 at DA Davidson Amid Progress on Back to Bricks Strategy
- BTIG Starts Freenome Inc. (FRNM) at Buy
- Goldman Sachs Starts Scribe Therapeutics Inc (SCTX) at Early-Stage Biotech
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
